Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CDC25B | P30305 | 2/20 | 0.52 |
| ▸ | CDC25A | P30304 | 1/20 | 0.52 |
| ▸ | CDC25C | P30307 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | ELANE | P08246 | 2/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3062533 | 0.98 | KMT2A (0.57) | KMT2AKDM4EMAPK1L3MBTL1CDC25B | |
| SCHEMBL27906657 | 0.85 | TSHR (0.53) | KDM4EMAPK1L3MBTL1CNR2TP53 | |
| SCHEMBL5935773 | 0.83 | TSHR (0.55) | KDM4EMAPK1L3MBTL1POLBRAB9A | |
| SCHEMBL30301713 | 0.82 | CNR2 (0.52) | KMT2AKDM4EL3MBTL1RAB9AMEN1 | |
| SCHEMBL7631322 | 0.82 | CNR2 (0.52) | KMT2AKDM4EL3MBTL1RAB9AMEN1 | |
| SCHEMBL8561476 | 0.81 | CYP2A6 (0.51) | KMT2AKDM4EMAPK1L3MBTL1CDC25B | |
| SCHEMBL5682388 | 0.81 | CNR2 (0.46) | KMT2AKDM4EMAPK1L3MBTL1CDC25B | |
| SCHEMBL11609998 | 0.80 | CNR2 (0.43) | KMT2AKDM4EMAPK1L3MBTL1CDC25B | |
| SCHEMBL2002683 | 0.80 | ALDH1A1 (0.49) | MAPK1POLBBRD4ELANEMAPT | |
| SCHEMBL7435091 | 0.79 | CDC25B (0.54) | KMT2AKDM4EMAPK1L3MBTL1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139859-B2 | Method for preparing (R)-praziquantel | TONGLI BIOMEDICAL CO., LTD (CN) | 2015-09-22 | — | — | US | disclosed |
| US-9068214-B2 | Method for preparing (R)-praziquantel | TONGLI BIOMEDICAL CO., LTD (CN) | 2015-06-30 | — | — | US | disclosed |
| US-20140370556-A1 | METHOD FOR PREPARING (R)-PRAZIQUANTEL | TONGLI BIOMEDICAL CO., LTD (CN) | 2014-12-18 | — | — | US | disclosed |
| US-20140370555-A1 | METHOD FOR PREPARING (R)-PRAZIQUANTEL | TONGLI BIOMEDICAL CO., LTD (CN) | 2014-12-18 | — | — | US | disclosed |
| CN-103145616-A | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN INC | 2013-06-12 | — | — | CN | disclosed |
| US-8258302-B2 | Method for producing benzazepinone | API CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20090171090-A1 | METHOD FOR PRODUCING BENZAZEPINONE | API CORPORATION (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090029995-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2009-01-29 | — | — | US | disclosed |
| EP-1985615-A1 | METHOD FOR PRODUCING BENZAZEPINONE | API Corporation (JP) | 2008-10-29 | — | — | EP | disclosed |
| EP-1553949-B1 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20040038959-A1 | 3-Isoquinolinone derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-02-26 | — | — | US | disclosed |
| US-20040038974-A1 | Chromone derivatives as matrix metalloproteinase inhibitors | ORTWINE DANIEL FRED (US) | 2004-02-26 | — | — | US | disclosed |
| US-20040038961-A1 | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-02-26 | — | — | US | disclosed |
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-02-26 | — | — | US | disclosed |
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | NAHRA JOE (US) | 2004-02-26 | — | — | US | disclosed |
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| WO-2004014379-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| US-6635647-B2 | Such as (4-(3,4-difluoro-phenyl)-piperazin-1-yl)-((4,4,8)-2-(3-(6-methoxy-pyridin-3 -yl)-2-methyl-propyl)-decahydro-isoquinolin-4-yl)-methanone; schizophrenia, depression, anxiety, bipolar disorders | NOVARTIS AG (CH) | 2003-10-21 | — | — | US | disclosed |
| CN-1052004-C | Heterocyclic compounds, their production and use | TALCEDA CHEMICAL IND LTD (JP) | 2000-05-03 | — | — | CN | disclosed |
| CN-1034552-C | Improvements in and relating to organic compounds | LILLY CO ELI (US) | 1997-04-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029995-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP2, MMP3 | KMT2A 467/4885KDM4E 724/4885MAPK1 2862/4885 |
| US-20040038974-A1 | Chromone derivatives as matrix metalloproteinase inhibitors | MMP9, MMP20, MMP25 | KMT2A 3833/4885KDM4E 825/4885MAPK1 233/4885 |
| US-20090171090-A1 | METHOD FOR PRODUCING BENZAZEPINONE | NISCH, GABBR1, GABBR2 | KMT2A 1792/4885KDM4E 2342/4885MAPK1 4175/4885 |
| US-20040038959-A1 | 3-Isoquinolinone derivatives as matrix metalloproteinase inhibitors | MMP1, MMP9, MMP3 | KMT2A 3490/4885KDM4E 2033/4885MAPK1 461/4885 |
| US-20140370555-A1 | METHOD FOR PREPARING (R)-PRAZIQUANTEL | CYP3A5, POR, CYP3A43 | KMT2A 3375/4885KDM4E 1393/4885MAPK1 4478/4885 |
| US-20040038961-A1 | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors | MMP13, MMP9, MMP1 | KMT2A 1644/4885KDM4E 462/4885MAPK1 590/4885 |
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | MMP9, MMP3, MMP13 | KMT2A 3394/4885KDM4E 1030/4885MAPK1 269/4885 |
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | MMP13, MMP11, MMP9 | KMT2A 4041/4885KDM4E 2282/4885MAPK1 345/4885 |
| US-20140370556-A1 | METHOD FOR PREPARING (R)-PRAZIQUANTEL | CYP3A5, POR, CYP3A43 | KMT2A 3375/4885KDM4E 1393/4885MAPK1 4478/4885 |
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP11 | KMT2A 3890/4885KDM4E 1434/4885MAPK1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.